{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:20:51Z","timestamp":1791332451471,"version":"4.3.1"},"reference-count":83,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Juvenile idiopathic arthritis (JIA) associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, affecting 10\u201315% of patients, especially in oligoarticular JIA where its course may be faint. Therefore, JIA-U is one of the most challenging pediatric uveitis, associated with major ocular morbidity and possibly leading to irreversible structural ocular damage and to vision-threatening complications. Adequate management is crucial for avoiding visual impairment complications. Since the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDS), the visual prognosis of JIA-U has dramatically improved over the decades. Tumor necrosis factor-\u03b1 (TNF-\u03b1) blockers are the most used bDMARDs in treating JIA-U with large evidence of efficacy. However, inadequate response to these agents, either due to intolerance or inefficacy, may be observed, requiring a swap to other classes of immunosuppressive agents, including anti-IL-6, anti-CD20, and, more recently, JAK inhibitors. Tocilizumab is a humanized monoclonal antibody to the interelukin-6 receptor preventing IL-6 from binding to its soluble and membrane-bound receptors. A growing body of literature provides promising results about the efficacy of intravenous and subcutaneous tocilizumab in the treatment of JIA-U. A narrative review of the literature on this topic will improve our knowledge on the potential use of tocilizumab in JIA-U.<\/jats:p>","DOI":"10.3390\/children10030434","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T04:59:44Z","timestamp":1677128384000},"page":"434","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5686-0127","authenticated-orcid":false,"given":"Claudia","family":"Iannone","sequence":"first","affiliation":[{"name":"Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, Italy"},{"name":"Faculty of Medicine, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Marelli","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Costi","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Pellico","sequence":"additional","affiliation":[{"name":"Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, Italy"},{"name":"Faculty of Medicine, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamberto","family":"La Franca","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Ospedale San Raffaele, University Vita-Salute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[{"name":"Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, Italy"},{"name":"Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Miserocchi","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Ospedale San Raffaele, University Vita-Salute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"ref_1","first-page":"390","article-title":"International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40744-016-0040-4","article-title":"Juvenile Idiopathic Arthritis: Diagnosis and Treatment","volume":"3","author":"Giancane","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3899\/jrheum.130302","article-title":"Risk Markers of Juvenile Idiopathic Arthritis-Associated Uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry","volume":"40","author":"Pelajo","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-005-0087-3","article-title":"Incidence and Outcomes of Uveitis in Juvenile Rheumatoid Arthritis, a Synthesis of the Literature","volume":"244","author":"Carvounis","year":"2006","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile Idiopathic Arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3928\/0191-3913-19970301-09","article-title":"Prevalence of Uveitis in an Outpatient Juvenile Arthritis Clinic: Onset of Uveitis More Than a Decade After Onset of Arthritis","volume":"34","author":"Akdwnan","year":"1997","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/aes-2019-dmu-10","article-title":"Update on Biologic Therapies for Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"6","author":"Thomas","year":"2021","journal-title":"Ann. Eye Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis\u2013Associated Uveitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in Inflammation, Immunity, and Disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_10","first-page":"851","article-title":"Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent Insights into Targeting the IL-6 Cytokine Family in Inflammatory Diseases and Cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108322","DOI":"10.1016\/j.clim.2019.108322","article-title":"Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"211","author":"Sen","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrrheum.2015.20","article-title":"Uveitis Associated with Juvenile Idiopathic Arthritis","volume":"11","author":"Sen","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Standardization of Uveitis Nomenclature for Reporting Clinical Data (2005). Results of the First International Workshop. Am. J. Ophthalmol., 140, 509\u2013516.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","article-title":"Phenotypic Variability and Disparities in Treatment and Outcomes of Childhood Arthritis throughout the World: An Observational Cohort Study","volume":"3","author":"Consolaro","year":"2019","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12969-015-0018-8","article-title":"Characteristics of a Cohort of Children with Juvenile Idiopathic Arthritis and JIA-Associated Uveitis","volume":"13","author":"McCracken","year":"2015","journal-title":"Pediatr. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/09273948.2013.791701","article-title":"Review for Disease of the Year: Epidemiology of Juvenile Idiopathic Arthritis and Its Associated Uveitis: The Probable Risk Factors","volume":"21","author":"Heiligenhaus","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"461078","DOI":"10.1155\/2014\/461078","article-title":"The Role of Gender in Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"2014","author":"Moradi","year":"2014","journal-title":"J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.survophthal.2014.03.002","article-title":"Pathogenesis of Juvenile Idiopathic Arthritis Associated Uveitis: The Known and Unknown","volume":"59","author":"Makhotkina","year":"2014","journal-title":"Surv. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/09273941003678837","article-title":"Uveitis Related to Juvenile Idiopathic Arthritis: Familial Cases and Possible Genetic Implication in the Pathogenesis","volume":"18","author":"Terrada","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-3476(05)82541-7","article-title":"Human Leukocyte Antigen-DRB1*1104 in the Chronic Iridocyclitis of Pauciarticular Juvenile Rheumatoid Arthritis","volume":"121","author":"Giannini","year":"1992","journal-title":"J. Pediatr."},{"key":"ref_22","first-page":"1394","article-title":"Longitudinal Analysis of HLA Associated Risks for Iridocyclitis in Juvenile Rheumatoid Arthritis","volume":"18","author":"Giannini","year":"1991","journal-title":"J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/09273940902999356","article-title":"Immune Response Genes in Uveitis","volume":"17","author":"Du","year":"2009","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/eye.2011.255","article-title":"Current Concepts and Future Directions in the Pathogenesis and Treatment of Non-Infectious Intraocular Inflammation","volume":"26","author":"Lee","year":"2012","journal-title":"Eye"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2019.03.004","article-title":"Transcriptomic and Proteomic Analysis of Iris Tissue and Aqueous Humor in Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"100","author":"Ackermann","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"682327","DOI":"10.3389\/fped.2021.682327","article-title":"Long Term Experience in Patients With JIA-Associated Uveitis in a Large Referral Center","volume":"9","author":"Marelli","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-015-3231-3","article-title":"Clinical Management Algorithm of Uveitis Associated with Juvenile Idiopathic Arthritis: Interdisciplinary Panel Consensus","volume":"35","author":"Bou","year":"2015","journal-title":"Rheumatol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ophtha.2009.12.003","article-title":"Risk of Cataract Development among Children with Juvenile Idiopathic Arthritis-Related Uveitis Treated with Topical Corticosteroids","volume":"117","author":"Thorne","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5005\/jp-journals-10028-1226","article-title":"Steroid-Induced Glaucoma: An Avoidable Irreversible Blindness","volume":"11","author":"Kaushik","year":"2017","journal-title":"J. Curr. Glaucoma Pract."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Foeldvari, I., Maccora, I., Petrushkin, H., Rahman, N., Anton, J., de Boer, J., Calzada-Hern\u00e1ndez, J., Carreras, E., Diaz, J., and Edelsten, C. (2023). New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis\u2013Associated Uveitis and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res., acr.24963.","DOI":"10.1002\/acr.24963"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-Head, Randomised, Crossover Study of Oral versus Subcutaneous Methotrexate in Patients with Rheumatoid Arthritis: Drug-Exposure Limitations of Oral Methotrexate at Doses \u226515 Mg May Be Overcome with Subcutaneous Administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","article-title":"Current Evidence of Methotrexate Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach","volume":"52","author":"Simonini","year":"2013","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/bjo.2009.173542","article-title":"Azathioprine as a Treatment Option for Uveitis in Patients with Juvenile Idiopathic Arthritis","volume":"95","author":"Goebel","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ophtha.2007.12.011","article-title":"Mycophenolate Mofetil after Methotrexate Failure or Intolerance in the Treatment of Scleritis and Uveitis","volume":"115","author":"Sobrin","year":"2008","journal-title":"Ophthalmology"},{"key":"ref_35","first-page":"1107","article-title":"Consensus-Based Recommendations for the Management of Uveitis Associated with Juvenile Idiopathic Arthritis: The SHARE Initiative","volume":"77","author":"Constantin","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"251584142098457","DOI":"10.1177\/2515841420984572","article-title":"Recent Advances in the Treatment of Juvenile Idiopathic Arthritis\u2013Associated Uveitis","volume":"13","author":"Chen","year":"2021","journal-title":"Ophthalmol. Eye Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3899\/jrheum.171006","article-title":"Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis","volume":"45","author":"Cecchin","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12969-021-00630-1","article-title":"Golimumab in Juvenile Idiopathic Arthritis-Associated Uveitis Unresponsive to Adalimumab","volume":"19","author":"Lanz","year":"2021","journal-title":"Pediatr. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09273940600659393","article-title":"Etanercept (Enbrel)-Associated Inflammatory Eye Disease: Case Report and Review of the Literature","volume":"14","author":"Taban","year":"2006","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A Randomized, Placebo-Controlled, Double-Masked Clinical Trial of Etanercept for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/BOR.0000000000000491","article-title":"How Does Abatacept Really Work in Rheumatoid Arthritis?","volume":"30","author":"Bonelli","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for Severe Anti-Tumor Necrosis Factor \u03b1 Refractory Juvenile Idiopathic Arthritis-Related Uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3899\/jrheum.140410","article-title":"Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis","volume":"42","author":"Tappeiner","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","article-title":"The Therapeutic Potential of Anti-CD20","volume":"117","author":"Eisenberg","year":"2005","journal-title":"Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","article-title":"Long-Term Treatment with Rituximab in Severe Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"100","author":"Miserocchi","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","article-title":"Clinical Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis: Study Protocol for an Open-Label, Adalimumab Active-Controlled Phase 3 Clinical Trial (JUVE-BRIGHT)","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK Inhibitors in Refractory Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 Biology into Effective Treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/jir.2005.25.241","article-title":"Review: IL-6 Transsignaling: The In Vivo Consequences","volume":"25","author":"Jones","year":"2005","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/art.1780380204","article-title":"Role of Interleukin-1, Tumor Necrosis Factor \u03b1, and Interleukin-6 in Cartilage Proteoglycan Metabolism and Destruction Effect of in Situ Blocking in Murine Antigen- and Zymosan-Induced Arthritis","volume":"38","author":"Loo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI113921","article-title":"Synovium as a Source of Interleukin 6 in Vitro. Contribution to Local and Systemic Manifestations of Arthritis","volume":"83","author":"Guerne","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","article-title":"Correlation of Serum Interleukin-6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rheumatoid Arthritis","volume":"34","author":"Massa","year":"1991","journal-title":"Arthritis Rheum."},{"key":"ref_54","first-page":"396","article-title":"Elevated Serum Interleukin 6, Interferon-Gamma, and Tumor Necrosis Factor-Alpha Levels in Patients with Adult Still\u2019s Disease","volume":"25","author":"Hoshino","year":"1998","journal-title":"J. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"INTERLEUKIN-6 IN SERUM OF PATIENTS WITH POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Rheumatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic Significance of Interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s Disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab Inhibits Signal Transduction Mediated by Both MIL-6R and SIL-6R, but Not by the Receptors of Other Members of IL-6 Cytokine Family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int. Immunopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1006\/cyto.2002.2012","article-title":"Anti-Interleukin 6 (IL-6) Receptor Antibody Suppresses Castleman\u2019s Disease Like Symptoms Emerged in IL-6 Transgenic Mice","volume":"20","author":"Katsume","year":"2002","journal-title":"Cytokine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic Benefit of Blocking Interleukin-6 Activity with an Anti-Interleukin-6 Receptor Monoclonal Antibody in Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of Rheumatoid Arthritis with Humanized Anti-Interleukin-6 Receptor Antibody: A Multicenter, Double-Blind, Placebo-Controlled Trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in Patients with Adult-Onset Still\u2019s Disease Refractory to Glucocorticoid Treatment: A Randomised, Double-Blind, Placebo-Controlled Phase III Trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199403033300904","article-title":"Alleviation of Systemic Manifestations of Castleman\u2019s Disease by Monoclonal Anti-Interleukin-6 Antibody","volume":"330","author":"Beck","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/art.20944","article-title":"Therapeutic Efficacy of Humanized Recombinant Anti-Interleukin-6 Receptor Antibody in Children with Systemic-Onset Juvenile Idiopathic Arthritis","volume":"52","author":"Yokota","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","article-title":"Open Label Phase II Trial of Single, Ascending Doses of MRA in Caucasian Children with Severe Systemic Juvenile Idiopathic Arthritis: Proof of Principle of the Efficacy of IL-6 Receptor Blockade in This Type of Arthritis and Demonstration of Prolonged Clinical Improvement","volume":"7","author":"Woo","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti\u2013Tumor Necrosis Factor \u03b1 versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/09273948.2013.866254","article-title":"Tocilizumab for Severe Chronic Anterior Uveitis Associated with Juvenile Idiopathic Arthritis in a Pediatric Patient","volume":"22","author":"Tsang","year":"2014","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","article-title":"Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?","volume":"39","author":"Tappeiner","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00417-013-2466-5","article-title":"Tocilizumab for Retinal Vasoproliferative Tumor Secondary to Juvenile Idiopathic Arthritis-Associated Uveitis: A Case Report","volume":"252","author":"Mesquida","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3899\/jrheum.160231","article-title":"Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis","volume":"43","author":"Tappeiner","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients: TCZ for JIA-Associated Uveitis","volume":"69","author":"Calvo","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","article-title":"Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients","volume":"200","author":"Mesquida","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/09273948.2020.1817501","article-title":"Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis","volume":"29","author":"Maleki","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09273948.2019.1576910","article-title":"Epidemiology of Macular Edema in Uveitis","volume":"27","author":"Accorinti","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000320077","article-title":"Cystoid Macular Edema in Uveitis","volume":"Volume 47","author":"Coscas","year":"2010","journal-title":"Developments in Ophthalmology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","article-title":"Twenty-Four Month Follow-Up of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema","volume":"38","author":"Mesquida","year":"2018","journal-title":"Retina"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","article-title":"Long-Term Effects of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema","volume":"121","author":"Mesquida","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4155\/tde.14.118","article-title":"Subcutaneous Formulation of Tocilizumab for Treatment of Rheumatoid Arthritis","volume":"6","author":"Ogata","year":"2015","journal-title":"Ther. Deliv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3899\/jrheum.160908","article-title":"Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis\u2013Associated Uveitis","volume":"44","author":"Caballero","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/09273948.2019.1644350","article-title":"Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis: A Case Report","volume":"29","author":"Ramirez","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Marino, A., Marelli, L., Nucci, P., Caporali, R., and Miserocchi, E. (2023). Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis. Ocul. Immunol. Inflamm., 1\u20134.","DOI":"10.1080\/09273948.2022.2161916"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in Patients with Anti-TNF Refractory Juvenile Idiopathic Arthritis-Associated Uveitis (APTITUDE): A Multicentre, Single-Arm, Phase 2 Trial","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.12688\/f1000research.26058.1","article-title":"Interleukin-6 Signalling in Health and Disease","volume":"9","year":"2020","journal-title":"F1000Res"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/10\/3\/434\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:40:16Z","timestamp":1760121616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/10\/3\/434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":83,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["children10030434"],"URL":"https:\/\/doi.org\/10.3390\/children10030434","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]}}}